A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Everolimus (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TRACER
- Sponsors Novartis Pharmaceuticals
- 13 Apr 2017 Status changed from completed to discontinued.
- 05 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 16 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015,as reported by ClinicalTrials.gov.